The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $9.55 in the prior trading day, Kura Oncology Inc (NASDAQ: KURA) closed at $9.41, down -1.47%. In other words, the price has decreased by -$1.47 from its previous closing price. On the day, 1.65 million shares were traded. KURA stock price reached its highest trading level at $9.71 during the session, while it also had its lowest trading level at $9.35.
Ratios:
Our goal is to gain a better understanding of KURA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.00. For the most recent quarter (mrq), Quick Ratio is recorded 5.12 and its Current Ratio is at 5.12. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.UBS initiated its Buy rating on October 24, 2024, with a $27 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 18 ’25 when Burrows Francis sold 23,726 shares for $9.78 per share. The transaction valued at 231,931 led to the insider holds 33,735 shares of the business.
FRANCIS J BURROWS bought 23,726 shares of KURA for $231,934 on Dec 18 ’25. On Dec 09 ’25, another insider, Hasnain Faheem, who serves as the Director of the company, sold 10,000 shares for $10.98 each. As a result, the insider received 109,764 and left with 23,983 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KURA now has a Market Capitalization of 818834880 and an Enterprise Value of 288635840. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.99 while its Price-to-Book (P/B) ratio in mrq is 3.38. Its current Enterprise Value per Revenue stands at 2.775 whereas that against EBITDA is -1.208.
Stock Price History:
The Beta on a monthly basis for KURA is 0.23, which has changed by 0.29972374 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, KURA has reached a high of $12.49, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is -11.81%, while the 200-Day Moving Average is calculated to be 18.08%.
Shares Statistics:
The stock has traded on average 1.89M shares per day over the past 3-months and 1403940 shares per day over the last 10 days, according to various share statistics. A total of 87.02M shares are outstanding, with a floating share count of 84.15M. Insiders hold about 3.05% of the company’s shares, while institutions hold 96.05% stake in the company. Shares short for KURA as of 1765756800 were 8223035 with a Short Ratio of 4.34, compared to 1763078400 on 8744761. Therefore, it implies a Short% of Shares Outstanding of 8223035 and a Short% of Float of 9.47.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.45 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$1.18 and -$3.68 for the fiscal current year, implying an average EPS of -$2.35. EPS for the following year is -$2.38, with 9.0 analysts recommending between -$0.74 and -$3.82.
Revenue Estimates
14 analysts predict $80.25M in revenue. The current quarter. It ranges from a high estimate of $176.95M to a low estimate of $652.41k. As of. The current estimate, Kura Oncology Inc’s year-ago sales were $53.88MFor the next quarter, 14 analysts are estimating revenue of $87.17M. There is a high estimate of $301.6M for the next quarter, whereas the lowest estimate is $5M.
A total of 14 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $227.1M, while the lowest revenue estimate was $50.8M, resulting in an average revenue estimate of $128.85M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $199.63M in the next fiscal year. The high estimate is $337.43M and the low estimate is $14.32M.
